# EDGAR Filing Document

**Accession Number:** 0001314102
**File Stem:** 0001193125-25-270145
**Filing Date:** 2025-11
**Character Count:** 10666
**Document Hash:** 00b9299097788e3ad27ea8677dcd85be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-270145.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001193125-25-270145

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EyePoint Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001314102
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 262774444
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51122
- **FILM NUMBER:** 251459668

**BUSINESS ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-926-5000

**MAIL ADDRESS:**
- **STREET 1:** 480 PLEASANT STREET
- **STREET 2:** SUITE C400
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida Corp.
- **DATE OF NAME CHANGE:** 20080619

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** pSivida LTD
- **DATE OF NAME CHANGE:** 20050111

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, DC 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): November 6, 2025

## EyePoint Pharmaceuticals, Inc.

#### (Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-51122** | **26-2774444** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### 480 Pleasant Street

#### Watertown, MA 02472

#### (Address of Principal Executive Offices, and Zip Code)
(617) 926-5000

#### Registrant's Telephone Number, Including Area Code

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.001 | EYPT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01. Other Events.
On November 6, 2025, EyePoint Pharmaceuticals, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") to its effective registration statement on Form S-3 (File No. 333-290867) (the "Registration Statement"), filed with the U.S. Securities and Exchange Commission on October 14, 2025, which became automatically effective upon filing, covering the registered offering of up to $200,000,000 of shares of common stock, par value $0.001 per share, of the Company (the "Shares"), pursuant to the Controlled Equity Offering<sup>SM</sup> Sales Agreement (the "Sales Agreement"), dated August 5, 2020, with Cantor Fitzgerald & Co.

In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Hogan Lovells US LLP, relating to the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1 | [Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated August 5, 2020, by and between EyePoint Pharmaceuticals, Inc. and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit No 1.1 to the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 5, 2020)](http://www.sec.gov/Archives/edgar/data/1314102/000156459020036461/eypt-ex11_58.htm) |
| 5.1 | [Opinion of Hogan Lovells US LLP](d80838dex51.htm) |
| 23.1 | [Consent of Hogan Lovells US LLP (contained in Exhibit 5.1)](d80838dex51.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EYEPOINT PHARMACEUTICALS, INC.** | **EYEPOINT PHARMACEUTICALS, INC.** |
| Date: November 6, 2025 | By: | /s/ George O. Elston |
|  | Name: | George O. Elston |
|  | Title | Executive Vice President and Chief Financial Officer |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g80838g1104232929038.jpg) | <br> Hogan Lovells US LLP<br> 1735 Market Street, Floor 23<br> Philadelphia, PA 19103<br> T +1 267 675 4600<br> F +1 267 675 4601<br> www.hoganlovells.com |

---

November 6, 2025

Board of Directors

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street

Watertown, MA 02472

Ladies and Gentlemen:

We are acting as counsel to EyePoint Pharmaceuticals, Inc., a Delaware corporation (the "**Company**"), in connection with the issuance and sale of up to $200,000,000 of shares of common stock, par value $0.001 per share, of the Company (the "**Shares**"), from time to time and at various prices in an "at the market offering" pursuant to the terms of the Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated August 5, 2020 (the "**Agreement**"), by and between the Company and Cantor Fitzgerald & Co., as placement agent. The offering of the Shares by the Company is being made pursuant to its automatic registration statement on Form S-3, filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "**Act**"), on October 14, 2025 (as may be amended from time to time, the "**Registration Statement**"), including a base prospectus (the "**Base Prospectus**") that forms a part thereof and a prospectus supplement dated November 6, 2025 (the "**Prospectus Supplement**" and together with the Base Prospectus, the "**Prospectus**"). This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. § 229.601(b)(5), in connection with the Registration Statement.

For purposes of this opinion letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate basis on which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents submitted to us as copies (including pdfs). As to all matters of fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so relied on. This opinion letter is given, and all statements herein are made, in the context of the foregoing.

This opinion letter is based as to matters of law solely on the Delaware General Corporation Law, as amended. We express no opinion herein as to any other statutes, rules or regulations.

Based upon, subject to and limited by the foregoing, we are of the opinion that assuming such issuance does not exceed the Maximum Amount (as defined in the Agreement), following (i) issuance of the Shares pursuant to the terms of the Agreement, and (ii) receipt by the Company of the consideration for the Shares specified in the resolutions of the Board of Directors or a committee designated by the Board of Directors, the Shares will be validly issued, fully paid and nonassessable.

Hogan Lovells US LLP is a limited liability partnership registered in the state of Delaware. "Hogan Lovells" is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP, with offices in: Alicante Amsterdam Baltimore Beijing Berlin Birmingham Boston Brussels Colorado Springs Denver Dubai Dublin Dusseldorf Frankfurt Hamburg Hanoi Ho Chi Minh City Hong Kong Houston London Los Angeles Luxembourg Madrid Mexico City Miami Milan Minneapolis Monterrey Munich New York Northern Virginia Paris Philadelphia Riyadh Rome San Francisco São Paulo Shanghai Silicon Valley Singapore Tokyo Washington, D.C. For more information see www.hoganlovells.com.

------

EyePoint Pharmaceuticals, Inc. - 2 - November 6, 2025

This opinion letter has been prepared for use in connection with the Registration Statement and the Prospectus relating to the offer and sale of the Shares, and speaks as of the date hereof. We assume no obligation to advise of any changes in the foregoing subsequent to the date hereof.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Company's Current Report on Form 8-K to be filed with the Commission on the date hereof and to the reference to this firm under the caption "Legal Matters" in the Prospectus constituting a part of the Registration Statement. In giving this consent, we do not thereby admit that we are an "expert" within the meaning of the Act.

---

| |
|:---|
| Very truly yours, |
| /s/ HOGAN LOVELLS US LLP |
| HOGAN LOVELLS US LLP |

---